Compare Cytokinetics Inc (CYTK) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Motorola Solutions Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.50B), while Motorola Solutions Inc trades at $446.82 (market cap $74.20B). The key difference: Motorola Solutions Inc is far larger — about 8.7× Cytokinetics Inc's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Motorola Solutions Inc for 100 Days on average.
| CYTK | MSI | |
|---|---|---|
Market Cap | $8.50B | $74.20B |
Volume | 2,395,556 | 720,826 |
Sector | Health | Technology |
52-Week High | $87.26 | $491.24 |
52-Week Low | $54.76 | $363.83 |
Typical Hold Time | 19 Days | 100 Days |
Enterprise Value | $8.60B | $83.10B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
MSI trades at $448.48, down 1.72% on the day, amid a bearish technical signal. The company shows strong fundamentals with revenue growth to $11.68 billion in 2025 and a net income margin of 17.44%. Recent news highlights expansion in defense and public safety contracts, including a $139 million Louisiana deal and a $1.5 billion D-Fend acquisition, bolstering its security portfolio. Analyst consensus remains bullish with a $525.86 price target, though cash flow trends show significant investing outflows for growth initiatives.
The outlook for MSI is positive due to robust earnings beats, a record $15.6 billion backlog, and strategic acquisitions enhancing its market position. Risks include high valuation multiples, substantial debt levels, and execution challenges in integrating new acquisitions. Institutional confidence is evident from increased holdings and a $2 billion share repurchase authorization, supporting long-term shareholder value amid near-term cash flow pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
